Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction.

OBJECTIVES We examined the possible association between the missense Glu298Asp variant of the endothelial nitric oxide synthase (eNOS) gene and myocardial infarction (MI). BACKGROUND Endothelium-derived nitric oxide (NO) plays a key role in the regulation of vascular tone. Recently, we reported that a missense Glu298Asp variant in exon 7 of the eNOS gene is a possible genetic factor involved in the pathogenesis of coronary spasm. Endothelium-derived NO also has vasoprotective effects by suppressing platelet aggregation, leukocyte adhesion and smooth muscle cell proliferation. METHODS We screened 285 patients with an MI and 607 control subjects in Kumamoto Prefecture, Japan. Genotypes were determined by polymerase chain reaction-restriction fragment-length polymorphism analysis. RESULTS The frequency of the missense Glu298Asp variant was significantly higher in the MI group than in the control group (21.1% vs. 13.3%, p = 0.003, odds ratio 1.73 for the dominant effect of the eNOS T allele). Multiple logistic regression analysis showed that the missense Glu298Asp variant was an independent risk factor for MI, as was diabetes mellitus, hypertension, cigarette smoking, hypercholesterolemia and body mass index. CONCLUSIONS There was a significant association of the missense Glu298Asp variant of the eNOS gene with MI. This marker-disease association may be due to the impaired effects of NO on the cardiovascular system: dysregulation of vascular tone, platelet aggregation and leukocyte adhesion and smooth muscle cell proliferation, all of which promote coronary atherosclerosis and thrombosis.

[1]  C. D. Barry,et al.  Comparison of predicted and experimentally determined secondary structure of adenyl kinase , 1974, Nature.

[2]  K. Nakao,et al.  A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese , 1998, Human Genetics.

[3]  A. Gardemann,et al.  Gene polymorphism but not catalytic activity of angiotensin I-converting enzyme is associated with coronary artery disease and myocardial infarction in low-risk patients. , 1995, Circulation.

[4]  Aravinda Chakravarti,et al.  Methodology in medical genetics: An introduction to statistical methods , 1988 .

[5]  L. Baumgartner "We Need Each Other". , 1957, American journal of public health and the nation's health.

[6]  A. Maxwell,et al.  ACE gene typing , 1994, The Lancet.

[7]  A. Morice,et al.  Insertion/deletion polymorphism in the angiotensin-converting enzyme gene and risk of and prognosis after myocardial infarction. , 1996, Journal of the American College of Cardiology.

[8]  Henry A. Erlich,et al.  Enzymatic amplification of ?-globin genomic sequences and restriction site analysis for diagnosis of , 1985 .

[9]  K. Schappert,et al.  Molecular cloning and characterization of human endothelial nitric oxide synthase , 1992, FEBS letters.

[10]  J M Lalouel,et al.  Angiotensin-converting enzyme gene polymorphism is associated with myocardial infarction but not with development of coronary stenosis. , 1995, Circulation.

[11]  W. Kannel,et al.  Clinical misconceptions dispelled by epidemiological research. , 1995, Circulation.

[12]  F. Soubrier,et al.  PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). , 1992, Nucleic acids research.

[13]  A. Hassid,et al.  Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. , 1989, The Journal of clinical investigation.

[14]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[15]  S. Scherer,et al.  Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. , 1993, The Journal of biological chemistry.

[16]  T. Quertermous,et al.  Cloning and expression of a cDNA encoding human endothelium-derived relating factor/nitric oxide synthase. , 1992, The Journal of biological chemistry.

[17]  A. Maseri,et al.  Coronary artery spasm and vasoconstriction. The case for a distinction. , 1990, Circulation.

[18]  P. Tempst,et al.  Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[19]  C. Conti Coronary-artery spasm and myocardial infarction. , 1983, The New England journal of medicine.

[20]  T. Dawber,et al.  II. Coronary Heart Disease in the Framingham Study , 1957 .

[21]  T. Quertermous,et al.  Cloning and expression of a cDNA encoding human endothelium-derived relaxing factor/nitric oxide synthase. , 1992, The Journal of biological chemistry.

[22]  H. Yasue,et al.  Coronary Arterial Spasm in Ischemic Heart Disease and Its Pathogenesis: A Review , 1983, Circulation research.

[23]  P. Tsao,et al.  Is NO an endogenous antiatherogenic molecule? , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[24]  K. Mullis,et al.  Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. , 1985, Science.

[25]  R. Badenhop,et al.  A smoking–dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene , 1996, Nature Medicine.

[26]  L. Tiret,et al.  Departure from Hardy-Weinberg equilibrium should be systematically tested in studies of association between genetic markers and disease. , 1995, Circulation.

[27]  Philippe Amouyel,et al.  Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction , 1992, Nature.

[28]  Ancel Keys Coronary heart disease in seven countries. , 1971, The Medical journal of Australia.

[29]  A. M. Lefer,et al.  Nitric oxide: nature's naturally occurring leukocyte inhibitor. , 1997, Circulation.

[30]  M J Peach,et al.  Molecular cloning and expression of a cDNA encoding endothelial cell nitric oxide synthase. , 1992, The Journal of biological chemistry.

[31]  T. Dawber,et al.  Coronary heart disease in the Framingham study. , 1957, American journal of public health and the nation's health.

[32]  J. Erikssen,et al.  Insertion/deletion (I/D) polymorphism at the locus for angiotensin I‐converting enzyme and myocardial infarction , 1993, Clinical genetics.

[33]  K. Okumura,et al.  Effect of acetylcholine on the highly stenotic coronary artery: difference between the constrictor response of the infarct-related coronary artery and that of the noninfarct-related artery. , 1992, Journal of the American College of Cardiology.

[34]  U. Walter,et al.  NO at work , 1994, Cell.

[35]  J. Loscalzo,et al.  Nitric oxide and its role in the cardiovascular system. , 1995, Progress in cardiovascular diseases.

[36]  E. Braunwald,et al.  Coronary-artery spasm. , 1978, The New England journal of medicine.

[37]  A. Emery Methodology in medical genetics: An introduction to statistical methods , 1976 .

[38]  A. Gotto Interactions of the major risk factors for coronary heart disease. , 1986, The American journal of medicine.

[39]  T. Michel,et al.  Expression of constitutive endothelial nitric oxide synthase in human blood platelets. , 1995, Life sciences.

[40]  R Kreutz,et al.  A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. , 1995, The New England journal of medicine.